- Record: found
- Abstract: not found
- Article: not found
Phase 1 clinical safety, pharmacokinetics (PK), and activity of apilimod dimesylate (LAM‐002A), a first‐in‐class inhibitor of phosphatidylinositol‐3‐Phosphate 5‐Kinase (PIKfyve), in patients with relapsed or refractory B‐cell malignancies
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.